Myeliod sarcoma in cardio-phrenic angle after allogeneic peripheral blood stem cell transplantation
10.3969/j.issn.2095-4344.2013.27.015
- VernacularTitle:异基因外周血干细胞移植后的心膈角髓肉瘤★
- Author:
Yi HE
;
Xudong LI
;
Dongning WANG
;
Yuan HU
;
Wenwen WANG
;
Jiajun LIU
;
Dongjun LIN
;
Renwei HUANG
- Publication Type:Journal Article
- Keywords:
stem cells;
stem cel transplantation;
acute myeloid leukemia;
al ogeneic stem cel transplantation;
myeliod sarcoma;
cardio-phrenic angle;
chemotherapy;
radiotherapy;
stem cel photogranphs-supporting paper
- From:
Chinese Journal of Tissue Engineering Research
2013;(27):5041-5047
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND: Al ogeneic hematopoietic stem cel transplantation is the main method to cure leukemia, but the patients receiving al ogeneic hematopoietic stem cel transplantation stil have to face the risk of recurrence. Myeloid sarcoma is a rare extramedul ary relapse mode with worse clinical outcomes, so it is necessary to understand the characteristics of myeloid sarcoma and relative treatment methods. OBJECTIVE: To analyze the clinical characteristics and treatment methods of myeliod sarcomas in cardio-phrenic angle after al ogeneic peripheral blood stem cel transplantation. METHODS: One case was diagnosed as single myeloid sacoma in the cardio-phrenic angle after al ogeneic peripheral blood stem cel transplantation. The patient underwent surgical resection of the mass, chemotherapy and radiotherapy. The clinical effect, complications and survival situation were observed. RESULTS AND CONCLUSION: The patient suffered from bacteremia, fungal pneumonia and even life-threatening sepsis shock during two courses chemotherapies. Then, the patient received radiotherapy for mediastinum and the myeloid sacoma never relapsed. However, the patient suffered central nervous system leukemia after free of the disease for 25 months. Myeliod sarcoma after al ogeneic hematopoietic stem cel transplantation is rare and its manifestation is changeful. The diagnosis mainly depends on histopathology and immunohistochemistry. Surgery, chemotherapy, radiotherapy, second transplantation and molecular targeted drugs are the choices of treatment strategy. However, the optimal treatment strategy for individual patients remains to be determined.
